Roche melanoma drug helps patients live longer
Zurich, January 19, 2011
Roche Holding's promising new drug for patients with advanced skin cancer helps patients to live longer and without their disease getting worse, a late-stage trial has shown.
The news is likely to give Roche a boost as its pipeline hit a number of setbacks last year, shaking investors' confidence in the group.
Patients taking RG7204, which is also being developed with privately held Plexxikon, lived longer and for longer without their disease progressing compared to those taking dacarbazine, the current standard of care, the Swiss drugmaker said on Wednesday. - Reuters